Russia said it had fought against the Ukrainian ammunition depot and repulsed Russia's repeated attacks. On the 10th local time, the Russian Defense Ministry reported that the Russian army had taken control of a settlement in Donetsk on the same day, and attacked the Ukrainian ammunition depot, electronic warfare base stations, armored vehicles and other targets. Russian air defense forces shot down several rockets and dozens of drones of the Ukrainian army. In addition, the Russian army continued to crack down on Ukrainian personnel and equipment in Kursk region, Russia. On the same day, the General Staff of the Ukrainian Armed Forces issued a war report, saying that as of the afternoon of the 10th, the Ukrainian army had nearly 100 battles with the Russian army in Kharkov, Kupyansk, Hongliman and other areas. The Ukrainian army continued to hold its ground and repelled many Russian attacks.More support policies for specialization and innovation are brewing. According to the data of the Ministry of Industry and Information Technology, up to now, China has cultivated a total of 14,600 "little giant" enterprises with specialization and innovation, and more than 140,000 small and medium-sized enterprises with specialization and innovation. Over 80% of the "Little Giant" enterprises are located in strategic emerging industrial chains such as integrated circuits and aerospace, and the number of enterprises in future industry-related fields such as artificial intelligence and low-altitude economy is nearly 5,000. The reporter was informed that the relevant departments will study and formulate guidance on building a mechanism to promote the development and growth of specialized and innovative small and medium-sized enterprises, issue guidance on cultivating high-quality enterprises, continue to increase support for the cultivation of specialized and innovative small and medium-sized enterprises, and promote the "expansion, quality improvement and strong chain" of specialized and innovative groups. (Economic Information Daily)Ministry of Finance of the Republic of Korea: We will pay close attention to the financial and foreign exchange market trends and take adequate measures to curb excessive fluctuations in the foreign exchange market.
Huatai Securities: The policy overweight boosts consumption and is optimistic about the four main lines. Huatai Securities Research Report said that with the continuous efforts of promoting consumption policies, the large consumer sector ushered in the configuration window period and continued to be optimistic about the basic orientation and valuation repair of the consumer sector. It is suggested to pay attention to four main investment lines: 1) the rise of domestic products: the strength and brand power of domestic products in beauty care, home appliances, pets, textiles and clothing are constantly improving, occupying consumers' minds against the trend, and domestic products continue to lead; 2) Emotional consumption: the products on the supply side are continuously iterated, and the goods/services are built as a medium to convey emotional value, and the consumption on the demand side is superimposed to promote the continuous expansion of the tide play /IP economy; 3) New cost performance: The consumption concept of residents is becoming more and more rational, and the quality-price ratio has become the core of consumption decision-making. The new cost performance consumption focusing on "good but not expensive" is expected to continue to grow rapidly; 4) Consumption going to sea: Going to sea has become a necessary topic for consumer enterprises. Under the two-way catalysis of supply and demand, China enterprises are actively participating in global market competition and paying attention to brand/culture/service going to sea.NVIDIA's market value evaporated by 660 billion yuan overnight. On December 10th, local time, the three major US stock indexes collectively closed down, with the Dow down 0.35%, the Nasdaq down 0.25% and the S&P 500 index down 0.30%. Among them, NVIDIA fell by 2.69%, and its market value evaporated by 91.593 billion US dollars (about 664.047 billion yuan) overnight.SpaceX is valued at about $350 billion due to internal stock sales. According to an email sent to employees seen by the media, SpaceX and its investors have agreed to acquire the company's common stock of up to $1.25 billion at a price of $185 per share. This transaction values the rocket and satellite manufacturer owned by elon musk at about $350 billion. The memo said that the price of $185 per share was much higher than the valuation of $112 less than three months ago. The memorandum was further confirmed by insiders. According to the memo, only SpaceX offered to buy up to $500 million in common stock.
Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide
Strategy guide 12-13